Does body mass index influence the clinical stage, treatment response and course of the disease in patients with differentiated thyroid cancer?

Danuta Gesior-Perczak; Iwona Palyga; Monika Szymonek; Artur Kowalik; Agnieszka Walczyk; Janusz Kopczynski; Katarzyna Lizis-Kolus; Tomasz Trybek1; Estera Mikina; Dorota Szyska-Skrobot; Klaudia Gadawska-Juszczyk; Stefan Hurej; Artur Szczodry; Janusz Sluszniak; Ryszard Mezyk; Stanislaw Gozdz; Aldona Kowalska

doi:10.1530/endoabs.56.GP235

GP235

Prev Next

Section Contents Cite

Endocrine Abstracts (2018) 56 GP235 | DOI: 10.1530/endoabs.56.GP235

ECE2018 Guided Posters Thyroid Cancer - Diagnostics & Treatments (12 abstracts)

Does body mass index influence the clinical stage, treatment response and course of the disease in patients with differentiated thyroid cancer?

Danuta Gęsior-Perczak ¹ , Iwona Pałyga ¹ , Monika Szymonek ¹ , Artur Kowalik ² , Agnieszka Walczyk ¹ , Janusz Kopczyński ³ , Katarzyna Lizis-Kolus ¹ , Tomasz Trybek1 ¹ , Estera Mikina ¹ , Dorota Szyska-Skrobot ¹ , Klaudia Gadawska-Juszczyk ¹ , Stefan Hurej ¹ , Artur Szczodry ¹ , Janusz Słuszniak ⁴ , Ryszard Mężyk ⁵ , Stanisław Góźdź ^6, & Aldona Kowalska ^1,

Views

Author affiliations

¹Holycross Cancer Centre, Endocrinology Clinic, Kielce, Poland; ²Holycross Cancer Centre, Nuclear Medicine, Kielce, Poland; ³Holycross Cancer Centre, Surgical Pathology, Kielce, Poland; ⁴Holycross Cancer Centre, Surgical Oncology, Kielce, Poland; ⁵Holycross Cancer Centre, Cancer Epidemiology, Kielce, Poland; ⁶Jan Kochanowski University, Kielce, Poland; ⁷Holycross Cancer Centre, Oncology Clinic, Kielce, Poland.

Introduction: Obesity is a serious health problem worldwide, especially in well developed countries. It is a cause of various diseases, including thyroid cancer. The relationship between obesity and prognostic factors of thyroid cancer is uncertain.

Aim of the study: Evaluation of relationship between the body mass index (BMI) and clinicopathological features increasing the risk of poor clinical course, treatment response and clinical outcome in patients with differentiated thyroid cancer (DTC).

Material: The study included 1,181 patients with DTC (88% women and 12% men) who were treated at a single center from 2000 to 2016, who underwent retrospective assessment of BMI and clinicopathological features before surgery. The relationship between clinical features of treatment response (excellent, indeterminate, biochemically incomplete, structurally incomplete) or final status of the disease (remission, persistent disease, death) and BMI was evaluated. Patients were stratified according to BMI (underweight, normal weight, overweight and obesity according to World Health Organization classification). Statistical analysis was performed using univariate and multivariate logistic regression analysis.

Results: Median follow-up was 7.7 years (1–16 years). BMI did not affect the response to treatment or outcome of the disease (remission, persistent disease, death). Obesity was more prevalent in men (P=0.033) and was more common in patients ≥45 years of age (P=0.001). We found statistically significant relationship of advanced TNM stage (III-IV) with increases in BMI (P=0.029), however this association disappeared after adjusting for age of ≥45 years (P=0.832).

Conclusions: Obesity in our study is not associated with more aggressive clinicopathological features of cancer, it is not a risk factor for higher clinical stage of cancer, it is not a prognostic factor for poorer treatment response and clinical outcome in DTC patients.